Literature DB >> 28835305

Cannabinoid hyperemesis syndrome presentation to the emergency department: A two-year multicentre retrospective chart review in a major urban area.

Jeremy M Hernandez1, Jared Paty2, Ira M Price1.   

Abstract

OBJECTIVE: Cannabinoid hyperemesis syndrome (CHS) is a paradoxical side effect of cannabis use. Patients with CHS often present multiple times to the emergency department (ED) with cyclical nausea, vomiting, and abdominal pain, and are discharged with various misdiagnoses. CHS studies to date are limited to case series. The objective was to examine the epidemiology of CHS cases presenting to two major urban tertiary care centre EDs and one urgent care centre over a 2-year period.
METHODS: Using explicit variables, trained abstractors, and standardized abstraction forms, we abstracted data for all adults (ages 18 to 55 years) with a presenting complaint of vomiting and/or a discharge diagnosis of vomiting and/or cyclical vomiting, during a 2-year period. The inter-rater agreement was measured using a kappa statistic.
RESULTS: We identified 494 cases: mean age 31 (+/-11) years; 36% male; and 19.4% of charts specifically reported cannabis use. Among the regular cannabis users (>three times per week), 43% had repeat ED visits for similar complaints. Moreover, of these patients, 92% had bloodwork done in the ED, 92% received intravenous fluids, 89% received antiemetics, 27% received opiates, 19% underwent imaging, 8% were admitted to hospital, and 8% were referred to the gastroenterology service. The inter-rater reliability for data abstraction was kappa=1.
CONCLUSIONS: This study suggests that CHS may be an overlooked diagnosis for nausea and vomiting, a factor that can possibly contribute to unnecessary investigations and treatment in the ED. Additionally, this indicates a lack of screening for CHS on ED history, especially in quantifying cannabis use and eliciting associated symptoms of CHS.

Entities:  

Keywords:  cannabis; cannabis hyperemesis syndrome; hyperemesis; marijuana; vomiting

Mesh:

Substances:

Year:  2017        PMID: 28835305     DOI: 10.1017/cem.2017.381

Source DB:  PubMed          Journal:  CJEM        ISSN: 1481-8035            Impact factor:   2.410


  8 in total

1.  A case of cannabinoid hyperemesis syndrome highlighting related key paediatric issues.

Authors:  Cameron F Leveille; Robert M Issenman; April J Kam
Journal:  Paediatr Child Health       Date:  2020-06-15       Impact factor: 2.253

Review 2. 

Authors:  Sophia Badowski; Graeme Smith
Journal:  Can Fam Physician       Date:  2020-02       Impact factor: 3.275

Review 3.  Cannabis use during pregnancy and postpartum.

Authors:  Sophia Badowski; Graeme Smith
Journal:  Can Fam Physician       Date:  2020-02       Impact factor: 3.275

Review 4.  The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information.

Authors:  Arun Swaminath; Eric P Berlin; Adam Cheifetz; Ed Hoffenberg; Jami Kinnucan; Laura Wingate; Sarah Buchanan; Nada Zmeter; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

Review 5.  Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms.

Authors:  Marieka V DeVuono; Linda A Parker
Journal:  Cannabis Cannabinoid Res       Date:  2020-06-05

6.  Emergency Department and Radiological Cost of Delayed Diagnosis of Cannabinoid Hyperemesis.

Authors:  David I Zimmer; Ross McCauley; Varun Konanki; Joseph Dynako; Nuha Zackariya; Faadil Shariff; Joseph Miller; Sophia Binz; Mark Walsh
Journal:  J Addict       Date:  2019-01-01

Review 7.  The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review.

Authors:  Kevin M Takakuwa; Raquel M Schears
Journal:  Int J Emerg Med       Date:  2021-02-10

8.  Changes in Emergency Department Visits for Cannabis Hyperemesis Syndrome Following Recreational Cannabis Legalization and Subsequent Commercialization in Ontario, Canada.

Authors:  Daniel Thomas Myran; Rhiannon Roberts; Michael Pugliese; Monica Taljaard; Peter Tanuseputro; Rosalie Liccardo Pacula
Journal:  JAMA Netw Open       Date:  2022-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.